The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable

Published:2018-09-30 Issue:6 Volume:14 Page:410-416
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Chin-Lenn L.¹²^ORCID,De Boer R. H.¹,Segelov E.¹,Marx G. M.³⁴,Hughes T. M.³⁴,McCarthy N. J.⁵,White S. C.⁶,Foo S. S.⁷⁸,Rutovitz J. J.⁹,Della-Fiorentina S.¹⁰,Jennens R.¹¹,Antill Y. C.¹²,Tsoi D.¹³,Cronk M. F.¹⁴,Lombard J. M.¹⁵,Kiely B. E.¹⁰,Chirgwin J. H.¹⁶,Gorelik A.¹,Mann G. B.¹²

Affiliation:

1. The Royal Melbourne Hospital; Parkville VIC Australia

2. Royal Women's Hospital; Parkville VIC Australia

3. Sydney Adventist Hospital; Wahroonga NSW Australia

4. University of Sydney; Sydney NSW Australia

5. ICON Cancer Care Wesley; Auchenflower QLD Australia

6. Austin Health; Heidelberg VIC Australia

7. Epworth Eastern Hospital; Box Hill VIC Australia

8. St Vincent's Private Hospital; East Melbourne VIC Australia

9. Northern Haematology and Oncology Group; Wahroonga NSW Australia

10. Macarthur Cancer Therapy Centre; Campbelltown NSW Australia

11. Epworth Hospital; East Melbourne Australia

12. Cabrini Health; Malvern VIC Australia

13. St John of God Murdoch Hospital; Murdoch VIC Australia

14. Sunshine Coast Hospital and Health Services; Nambour QLD Australia

15. Calvary Mater Newcastle; Waratah NSW Australia

16. Eastern Health; Box Hill VIC Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.13075/fullpdf

Reference26 articles.

1. Cancer statistics, 2014;Siegel;Cancer J Clin.,2014

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials;EBCTCG;Lancet,2012

3. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

4. Prospective validation of a 21-gene expression assay in breast cancer;Sparano;N Engl J Med,2015

5. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant chemotherapy for pT1-3N0-1 breast cancer patients with HR+, HER2− subtype: a propensity-score matched study with competing risk analysis;Journal of Cancer Research and Clinical Oncology;2023-07-14

2. Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review;PLOS ONE;2023-03-10

3. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec;The Oncologist;2022-07-13

4. The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience;Current Oncology;2022-03-16

5. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting;The Breast Journal;2022-01-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3